Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) Director Richard A. Heyman sold 518 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $27.54, for a total value of $14,265.72. Following the sale, the director now owns 128,585 shares of the company’s stock, […]

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) insider Joseph P. Lyssikatos sold 527 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $27.54, for a total transaction of $14,513.58. Following the sale, the insider now owns 1,077,409 shares of the company’s stock, […]

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) CFO Benjamin Hohl sold 4,250 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The shares were sold at an average price of $24.27, for a total transaction of $103,147.50. The sale was disclosed in a document filed with the SEC, which […]

Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) CEO Stephen F. Mahoney acquired 21,400 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The shares were bought at an average cost of $23.33 per share, with a total value of $499,262.00. Following the completion of the purchase, the chief executive […]